Perhaps most importantly, knowledge of a patient’s genomic status may be relevant in selecting an optimal induction regimen, such as all-trans retinoic acid plus arsenic trioxide for acute promyelocytic leukemia46, adding GO in core binding factor AML47, CPX-351 in patients with myelodysplasia-related changes of therapy-related AML48, adding midostaurin for FLT3-mutated AML47, or considering IDH inhibitor-based approaches for IDH-mutant AML. Here, FLT3 is linked to Myelodysplasia.